(March 20, 2019) Earlier this month, OCRA united advocates from across the country for Spring Advocacy Day on Capitol Hill. Together, this passionate group of survivors, caregivers and supporters used their collective voice to advocate for increased funding for ovarian cancer research and education. Learn more about our asks for Ovarian Cancer Research Program (OCRP) … Continued
(March 19, 2019) Congress is considering a $15 million increase for OCRP funding. Urge YOUR Representative to sign the letter to help push this funding through. Deadline is March 25th! Tell Congress to Increase OCRP Funding The Ovarian Cancer Research Program (OCRP) is a cutting-edge program housed within the Department of Defense and despite a … Continued
(March 12, 2019) “The President’s proposed FY2020 budget released by the White House on Monday seeks to cut medical research funding at the National Cancer Institute (NCI) by 15 percent – almost $900 million dollars compared to FY2019 funding. The budget also slashes the Centers for Disease Control’s (CDC) Chronic Disease Program by almost 20 … Continued
Be a voice for the ovarian cancer community. Update: The deadline to apply for our 2019 Advocate Leader program has now passed. (August 28, 2018) Registration is now open for our 2019 Advocate Leader program. Apply today to join our diverse community of survivors, caregivers and activists from across the country using their voices to effect … Continued
Name: Sayla H.Hometown: Portland, ORStatus: In treatmentAdvocacy Goal: Oral Parity, Access to Care Sayla was diagnosed earlier last year and is currently in treatment. She’s determined to use her experience to help other women, and is empowered to advocate for women fighting ovarian cancer through OCRA’s Advocate Leader program. Tell us about your ovarian cancer … Continued
Name: Elise D.Hometown: Durham, NHStatus: 13-Year SurvivorAdvocacy Goal: Access to Care Elise feels lucky that she was diagnosed with early-stage ovarian cancer, and being an Advocate Leader allows her to fight for women who may not be able to fight for themselves. Tell us about your ovarian cancer journey. In the summer of 2005, I … Continued
(Oct. 11, 2017) Last week, the Trump Administration issued a regulation to immediately allow employers to deny insurance coverage for birth control on the basis of their own moral or religious objections, undermining the landmark benefit under the Affordable Care Act (ACA) that guarantees coverage for contraception without co-pays or cost-sharing. Audra Moran, President and … Continued
According to recent reports, the Department of Health and Human Services (HHS) will soon seek to limit access to oral contraception benefits. “The proposed rule allowing employers to deny insurance coverage for birth control limits the application of oral contraceptives in preventive medicine, in particular, for ovarian cancer. Oral contraceptives have been shown to reduce … Continued
The White House has released a proposed budget for FY2018 that makes drastic cuts to the budgets for the National Institute of Health (NIH) and Centers for Disease Control and Prevention (CDC). These cuts would reduce the NIH budget by 20% and threaten to halt breakthrough medical research advancements and delay life-saving cures. The proposed … Continued
As the voice for women with ovarian cancer on Capitol Hill, OCRFA fights to secure funding for ovarian cancer research and education at the federal level. In 2016, with the help of committed Advocate Leaders, Grassroots Advocates, Research Advocates and action alert supporters, OCRFA was able to: We’ve made great strides in ensuring that ovarian … Continued
The Kolker Fellowship commemorates the legacy of pioneering health policy advocate Ann Kolker. At the time Ann was diagnosed with ovarian cancer in 1996, she was already a political powerhouse, having early involvement with organizations like the National Women’s Political Caucus and Emily’s List. We are now accepting applications for the Fall 2017 Fellowship.
On September 7th, the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated. The FDA states, “despite extensive research and published studies, there are currently no screening tests for ovarian cancer that are sensitive enough to reliably screen for ovarian cancer without a … Continued
Get email updates about research news, action alerts, and ways to join the fight.
